Concepedia

Lisa Aschenbrenner

LA

Statistics

Publications

16

Citations

3K

H-Index

16

Active since

2010

Affiliations

Pfizer (United States)(Current)

Utah State University

California Institute for Biomedical Research

Scripps Research Institute

Purdue University West Lafayette

Lisa Aschenbrenner is an author at Pfizer (United States) specializing in drug discovery, antiviral therapy, and antiviral pharmacology.

Publications per year

2010–2025

16

Publications

16

An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.9K citations · Full text

Medicine, Infectious Diseases, Pharmacology +13

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · Nature Communications · 2021 · 296 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +15

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 159 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Acoustic Ejection Mass Spectrometry for High-Throughput Analysis

Hui Zhang, Chang Liu, Wenyi Hua et al. · Analytical Chemistry · 2021 · 106 citations · Full text

Natural Sciences, Pharmacokinetics, Pharmacology +13

Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam

Craig J. McPherson, Lisa Aschenbrenner, Brian M. Lacey et al. · Antimicrobial Agents and Chemotherapy · 2012 · 89 citations · Full text

Life Sciences, Medicinal Chemistry, Antimicrobial Resistance +16

1–5 of 16